ARCT (Arcturus Therapeutics Holdings) EBIT per Share: $-2.79 (TTM As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
56 GF Score
Price $6.72
GF Value $4.15
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings EBIT per Share?

Arcturus Therapeutics Holdings ARCT -1.47% 56 EBIT per Share is $-2.79 as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 56/100 and a GF Value™ of $4.15 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,180 Biotechnology companies, Arcturus Therapeutics Holdings ranks worse than 84745.68% on this metric.

Arcturus Therapeutics Holdings's EBIT per Share for the three months ended in Mar. 2026 was $-1.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.79.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Arcturus Therapeutics Holdings's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Arcturus Therapeutics Holdings was 58.90% per year. The lowest was -90.30% per year. And the median was -0.65% per year.

ARCT's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Arcturus Therapeutics Holdings's EBIT for the three months ended in Mar. 2026 was $-28.93 Mil.

Arcturus Therapeutics Holdings  (NAS:ARCT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Arcturus Therapeutics Holdings EBIT per Share Related Terms

Arcturus Therapeutics Holdings EBIT per Share Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings EBIT per Share Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.71 0.45 -1.02 -3.00 -2.40

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.43 -0.61 -0.74 -1.02
ARCT
56GF Score
Arcturus Therapeutics Holdings Inc ARCT
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Arcturus Therapeutics Holdings's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-65.774/27.386
=-2.40

Arcturus Therapeutics Holdings's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-28.931/28.421
=-1.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-2.79 mean?
Arcturus Therapeutics Holdings (ARCT) has a EBIT per Share of $-2.79 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arcturus Therapeutics Holdings and its competitors. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1180 companies in the Biotechnology industry.
Is Arcturus Therapeutics Holdings' EBIT per Share too high?
Arcturus Therapeutics Holdings' current EBIT per Share is $-2.79. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1180 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' EBIT per Share compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #999999 out of 1180 companies for EBIT per Share. This places Arcturus Therapeutics Holdings in the lower half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current EBIT per Share is $-2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.15, compared to a current price of $6.72 — trading 61.9% above its estimated fair value. The current EBIT per Share is $-2.79. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current EBIT per Share is $-2.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.72 is trading 61.9% above its estimated GF Value™ of $4.15. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • EBIT per Share: $-2.79
  • GF Value™: $4.15 vs. price of $6.72 (61.9% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score

Get the complete analysis for ARCT

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.72
Price
$4.15
GF Value